Rituximab in relapsing Graves' disease, a phase II study

Area of Science:

• Endocrinology
• Immunology
• Pharmacology

Background:

• Graves' disease is an autoimmune disorder causing hyperthyroidism.
• Conventional treatments like antithyroid drugs and radioiodine have limitations in efficacy and side effects.
• Targeting the autoimmune pathogenesis may offer a more effective therapeutic approach.

Purpose of the Study:

• To assess the efficacy and safety of rituximab in patients with recurrent Graves' disease.
• To evaluate the impact of rituximab on thyroid hormone levels and autoimmune markers.
• To explore rituximab as a potential treatment for the underlying autoimmune cause of Graves' disease.

Main Methods:

• A prospective, 26-week phase II study with an open-ended observational extension.
• Thirteen patients with relapsing Graves' disease received two doses of 1000 mg rituximab intravenously.
• Measurements included thyroid-stimulating hormone (TSH), free thyroxine (FT4), thyrotropin binding inhibitory immunoglobulins (TBII), and lymphocyte populations (CD19, MS4A1).

Main Results:

• Rituximab significantly reduced MS4A1 positive lymphocytes (P=0.007).
• A significant decrease in FT4 levels (P=0.001) and increase in TSH levels (P=0.011) were observed in responding patients.
• Thyrotropin binding inhibitory immunoglobulins decreased significantly (P=0.003), and nine patients remained euthyroid at long-term follow-up (14-27 months).

Conclusions:

• Rituximab demonstrates a beneficial effect in patients with mild, relapsing Graves' disease.
• The drug appears to modulate the autoimmune process underlying Graves' disease.
• A randomized controlled trial is warranted to confirm these findings and establish rituximab's role in Graves' disease management.